Education
About Us
Working with TipRanks
Follow Us
Angiodynamics, Inc. (ANGO)
:ANGO
Earnings Data
Report Date
Jul 09, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.06Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 02, 2025
|% Change Since: -0.62%
|Next Earnings Date:Jul 09, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and profitability improvements, particularly in the MedTech and Mechanical Thrombectomy segments. The company increased its guidance for fiscal 2025, indicating confidence in future performance. However, there are ongoing challenges with NanoKnife reimbursement and minimal growth in the Med Device segment. Overall, the positive aspects significantly outweigh the lowlights.Company Guidance
During the AngioDynamics Fiscal Year 2025 Third Quarter Earnings Call, the company increased its guidance for the year following strong performance. Total worldwide revenue was reported at $72 million, marking a 9% year-over-year increase. The MedTech segment grew by 22%, driven by platforms like Auryon, which saw a 17% increase, and the Mechanical Thrombectomy business, which grew by approximately 47%. The company's gross margin improved to 54%, up by 290 basis points compared to the previous year. Adjusted EBITDA turned positive at $1.3 million, contrasting with a $3.6 million loss in the same quarter of the previous fiscal year, and adjusted EPS was a loss of $0.08 per share, an improvement from the $0.16 loss per share recorded last year. AngioDynamics' updated guidance projects fiscal 2025 total revenue between $285 million and $288 million, with MedTech growth expected to be 14% to 16% and a gross margin range of 53% to 54%.Strong Revenue Growth
Total worldwide revenue was $72 million, representing growth of over 9% year-over-year. MedTech segment grew 22%, and Auryon platform revenue increased by 17%.
Mechanical Thrombectomy Segment Success
Mechanical Thrombectomy products, AlphaVac and AngioVac, in combination grew approximately 47% over the second quarter of last year. AlphaVac revenue increased by over 160%.
Improving Profitability
Reported positive adjusted EBITDA of $1.3 million compared to a loss of $3.6 million in the prior year. Adjusted EPS loss improved from $0.16 to $0.08 per share.
Guidance Increase
Guidance increased for total revenue, MedTech growth, gross margin, adjusted EBITDA, and adjusted EPS for the fiscal year 2025.
---
ANGO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ANGO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 02, 2025 | $9.66 | $10.86 | +12.42% |
| Jan 08, 2025 | $9.40 | $12.94 | +37.66% |
| Oct 03, 2024 | $7.65 | $6.37 | -16.73% |
| Jul 16, 2024 | $5.93 | $7.51 | +26.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Angiodynamics, Inc. (ANGO) report earnings?
Angiodynamics, Inc. (ANGO) is schdueled to report earning on Jul 09, 2025, TBA Not Confirmed.
What is Angiodynamics, Inc. (ANGO) earnings time?
Angiodynamics, Inc. (ANGO) earnings time is at Jul 09, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANGO EPS forecast?
ANGO EPS forecast for the fiscal quarter 2025 (Q4) is -0.12.
---
